Sanofi (SNY) |
|
54.42 0.45 (0.83%)
|
03-31 16:00 |
|
Open: |
54.43 |
Pre. Close: |
53.97 |
|
High:
|
54.52 |
Low:
|
54.16 |
|
Volume:
|
2,019,692 |
Market Cap:
|
135,910(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:22:12 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 63.93 One year: 74.67 |
| Support: |
Support1: 49.85 Support2: 46.83 |
| Resistance: |
Resistance1: 54.74 Resistance2: 63.93 |
| Pivot: |
50.55  |
| Moving Average: |
MA(5): 54.04 MA(20): 49.75
MA(100): 47.62 MA(250): 47.46 |
| MACD: |
MACD(12,26): 1.7 Signal(9): 1 |
| Stochastic oscillator: |
%K(14,3): 94  %D(3): 95.7 |
| RSI: |
RSI(14): 78.5 |
| 52-week: |
High: 58.09 Low: 36.9 |
| Average Vol(K): |
3-Month: 2,011 (K) 10-Days: 2,199 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SNY ] has closed below upper band by 16.3%. Bollinger Bands are 244.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
54.58 - 54.8 |
54.8 - 54.99 |
|
Low:
|
53.55 - 53.82 |
53.82 - 54.06 |
|
Close:
|
53.96 - 54.39 |
54.39 - 54.77 |
|
Company Description |
|
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. |
Headline News |
Mon, 27 Mar 2023
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know - Nasdaq
Mon, 27 Mar 2023
Sanofi SA (SNY) Up 1.18% in Premarket Trading - InvestorsObserver
Sun, 26 Mar 2023
Ellsworth Advisors LLC Invests $441000 in Sanofi (NASDAQ:SNY) - MarketBeat
Thu, 23 Mar 2023
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study - Nasdaq
Tue, 21 Mar 2023
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids - Nasdaq
Tue, 21 Mar 2023
Sanofi (SNY) Gains But Lags Market: What You Should Know - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,510 (M) |
| Shares Float |
2,220 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
10.3 (%) |
|
Shares Short
|
2,960 (K) |
|
Shares Short P.Month
|
2,840 (K) |
Stock Financials |
|
EPS
|
5.84 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
25.19 |
|
Profit Margin (%)
|
14.8 |
|
Operating Margin (%)
|
26.1 |
|
Return on Assets (ttm)
|
6 |
|
Return on Equity (ttm)
|
9.5 |
|
Qtrly Rev. Growth
|
10 |
|
Gross Profit (p.s.)
|
12.62 |
|
Sales Per Share
|
18.08 |
|
EBITDA (p.s.)
|
5.8 |
|
Qtrly Earnings Growth
|
29.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
9.31 |
|
PEG Ratio
|
0.8 |
|
Price to Book value
|
2.16 |
|
Price to Sales
|
3 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2021-05-25 |
|
Ex-Dividend Date
|
2021-05-02 |
|
Your Ad Here
|
|
